- Home ›
- Compliance challenges in China’s life sciences sector
Compliance challenges in China’s life sciences sector
Compliance challenges in China’s life sciences sector
Our View - Issue X, December 2015
In this issue of “Our view”, we highlight China’s evolving stricter regulatory regime – stemming from government initiatives to improve corruption-related compliance – and discuss various issues unfolding in the country’s life sciences/pharmaceutical sector, given the wider implications for M&A and investment into China.
Key points of interest include:
- trends, and counter-trends, emerging in the life sciences/pharmaceutical industry given the potential for such issues to crystallize in M&A transactions
- China’s increasingly stringent regulatory regime and the need for deeper awareness of corruption-related compliance
- measures being taken to foil ever-more sophisticated tactics by employees/third parties to circumvent potentially outdated controls.
© 2024 KPMG Huazhen LLP, a People's Republic of China partnership, KPMG Advisory (China) Limited, a limited liability company in Chinese Mainland, KPMG, a Macau (SAR) partnership, and KPMG, a Hong Kong (SAR) partnership, are member firms of the KPMG global organisation of independent member firms affiliated with KPMG International Limited, a private English company limited by guarantee. All rights reserved.
The KPMG name and logo are trademarks used under license by the
independent member firms of the KPMG global organisation.
For more detail about the structure of the KPMG global organisation please visit https://kpmg.com/governance.
Connect with us
- Find office locations kpmg.findOfficeLocations
- kpmg.emailUs
- Social media @ KPMG kpmg.socialMedia
Stay up to date with what matters to you
Gain access to personalized content based on your interests by signing up today